- Home
- MGNI vs AKRO Comparison
MGNI vs AKRO Comparison
Compare MGNI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNI
- AKRO
- Stock Information
- Founded
- MGNI 2007
- AKRO 2017
- Country
- MGNI United States
- AKRO United States
- Employees
- MGNI N/A
- AKRO N/A
- Industry
- MGNI Computer Software: Programming Data Processing
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- MGNI Technology
- AKRO Health Care
- Exchange
- MGNI Nasdaq
- AKRO Nasdaq
- Market Cap
- MGNI 1.7B
- AKRO 2.1B
- IPO Year
- MGNI N/A
- AKRO 2019
- Fundamental
- Price
- MGNI $12.94
- AKRO $31.59
- Analyst Decision
- MGNI Strong Buy
- AKRO Strong Buy
- Analyst Count
- MGNI 11
- AKRO 7
- Target Price
- MGNI $16.95
- AKRO $43.20
- AVG Volume (30 Days)
- MGNI 1.3M
- AKRO 441.5K
- Earning Date
- MGNI 11-07-2024
- AKRO 11-11-2024
- Dividend Yield
- MGNI N/A
- AKRO N/A
- EPS Growth
- MGNI N/A
- AKRO N/A
- EPS
- MGNI N/A
- AKRO N/A
- Revenue
- MGNI $649,216,000.00
- AKRO N/A
- Revenue This Year
- MGNI $0.26
- AKRO N/A
- Revenue Next Year
- MGNI $10.75
- AKRO N/A
- P/E Ratio
- MGNI N/A
- AKRO N/A
- Revenue Growth
- MGNI 7.50
- AKRO N/A
- 52 Week Low
- MGNI $6.46
- AKRO $11.36
- 52 Week High
- MGNI $15.92
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- MGNI 54.59
- AKRO 66.34
- Support Level
- MGNI $12.35
- AKRO $29.34
- Resistance Level
- MGNI $13.11
- AKRO $32.15
- Average True Range (ATR)
- MGNI 0.42
- AKRO 1.26
- MACD
- MGNI 0.11
- AKRO 0.10
- Stochastic Oscillator
- MGNI 63.58
- AKRO 99.74
About MGNI Magnite Inc.
Magnite is one of the largest supply-side platform providers, or SSP, in online advertising. The firm was previously named The Rubicon Project (an online ad exchange) and became Magnite after merging with Telaria (an SSP focused mainly on streaming video providers) in 2020. The firm also purchased another of the leading SSPs within the CTV market, SpotX, in 2021 for $1.2 billion, cementing its long-term focus on grabbing market share in this area. The firm generates nearly 45% of its revenue from the programmatic sale of CTV ad inventory, 35% from mobile online sites and apps, and the remaining from websites accessed via computer.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.